SET/TAF-I antibody (AA 147-235) (HRP)

Catalog No. ABIN7166109

Product Details anti-SET/TAF-I Antibody (HRP)

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Binding Specificity: AA 147-235

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SET/TAF-I antibody is conjugated to HRP

Application: ELISA

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Protein SET protein (147-235AA)

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for SET/TAF-I

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Alternative Name: SET (SET Products)

Synonyms: 2PP2A antibody, I2PP2A antibody, IGAAD antibody, IPP2A2 antibody, PHAPII antibody, TAF-I antibody, TAF-IBETA antibody, 2610030F17Rik antibody, 5730420M11Rik antibody, AA407739 antibody, I-2PP2A antibody, StF-IT-1 antibody, 2pp2a antibody, i2pp2a antibody, igaad antibody, ipp2a2 antibody, phapii antibody, set antibody, set-a antibody, set-b antibody, taf-ibeta antibody, wu:fb30g11 antibody, wu:fd16c08 antibody, SET nuclear proto-oncogene antibody, SET nuclear oncogene antibody, SET translocation antibody, SET nuclear proto-oncogene L homeolog antibody, SET nuclear proto-oncogene b antibody, SET antibody, Set antibody, LOC403555 antibody, set.L antibody, setb antibody

Background:

Background: Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins, however, isoform 2 specific activity is higher.

Aliases: 2PP2A antibody, HLA DR associated protein II antibody, HLA-DR-associated protein II antibody, I 2PP2A antibody, I-2PP2A antibody, I2PP2A antibody, IGAAD antibody, Inhibitor of granzyme A activated DNase antibody, Inhibitor of granzyme A-activated DNase antibody, Inhibitor of GzmA-activated DNase antibody, inhibitor-2 of protein phosphatase-2A antibody, IPP2A2 antibody, PHAPII antibody, Phosphatase 2A inhibitor I2PP2A antibody, protein phosphatase type 2A inhibitor antibody, Protein SET antibody, Set antibody, SET nuclear oncogene antibody, SET translocation antibody, SET translocation (myeloid leukemia-associated) antibody, SET_HUMAN antibody, TAF I antibody, TAF IBETA antibody, TAF-I antibody, TAFI antibody, Template activating factor I antibody, Template-activating factor I antibody, Template-Activating Factor-I, chromatin remodelling factor antibody

UniProt: Q01105

Pathways: Apoptosis